Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha
- 1 October 1991
- journal article
- Published by Elsevier in The American Journal of Surgery
- Vol. 162 (4) , 384-387
- https://doi.org/10.1016/0002-9610(91)90154-6
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Interleukin‐2 injected around tumor‐draining lymph nodes in head and neck cancerHead & Neck, 1991
- Recombinant Interleukin-2 and Adoptive Immunotherapy Alternated With Dacarbazine Therapy in Melanoma: A National Biotherapy Study Group TrialJNCI Journal of the National Cancer Institute, 1990
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Synergism between Alpha-Interferon and Interleukin-2-Activated Killer Cells: In vitro StudiesActa Haematologica, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- T-lymphocyte/monocyte interaction in response to phytohemagglutininCellular Immunology, 1979
- Recurrent head and neck cancer: The results of treatmentBritish Journal of Surgery, 1974